Method for treating iodine-deficient states in pregnant women

FIELD: medicine, obstetrics.

SUBSTANCE: along with conventional therapy that includes introduction of iodine-containing preparations one should additionally introduce iodine-containing product obtained out of brown algae - "Lamifaren", per 50 g once daily, in the morning, about 30-40 min before meals, naturally with juices or dairy products, every day during 2 mo since the moment of the primary inspection. The innovation enables to increase efficiency of therapy due to high biodigestibility of "Lamifaren".

EFFECT: higher efficiency of therapy.

4 ex, 1 tbl

 

The invention relates to medicine, in particular to obstetrics, gynecology, internal medicine, endocrinology, and can be used to treat deficiency States (IDS) as in pregnant women, and other groups.

There are ways of treatment, consisting in the fact that prescribed drugs iodine and contains (Avireal, Oaaea, Tseminyu and others, 2000; Geshelin, 2000; Saimira, Dai, 2001). The closest analogue prototype is a technique in which the use of potassium iodide (Kurmasheva N.A., Shalagina L.A. // Russian journal of pediatric. - 2003. No. 3. - P.26-28). Not effective enough. Goal: improve the quality of treatment IDS pregnant women and other groups.

The task is solved in that in addition to preparations containing potassium iodide, designate "Lamifiban", which is the diet (therapeutic and prophylactic) of iodine-containing product, natural enterosorbent. "Lamifiban" - chilled gel is a natural product consistency similar to applesauce with odor and taste characteristic of the seaweed. While it is prescribed at 50 g 1 in the morning for 30-40 minutes before eating natural fruit juices or milk products daily for 2 months after the initial survey.

The advantages of the proposed method:

- contains biologically and is active iodine;

- enterosorbent of natural origin.

For disclosure of the invention the results of studies on the clinical and laboratory efficiency of the proposed method for the prevention and treatment IDS.

Used diet (therapeutic and prophylactic) product "Lamifiban"containing biologically active iodine. Thanks to its properties it is natural enterosorbent. The product is designed and manufactured from brown algae Laminaria Japonica using a unique low-temperature technology (Patent for invention №2230464) SEC RK "Space" (General Director Smolkov, glovatsky Gavan, Khabarovsk). Approved for use SES (Sanitary-epidemiological conclusion No. D from 22.09.2003,).

Evaluation of the effectiveness of treatment IDS carried out in two groups of pregnant women (see table). The first group consisted of 84 pregnant women treated with the drug "Potassium iodide-200" (pharmaceutical company "Berlin-Chemie") and optional iodine-containing therapeutic product "Lamifiban". The second group consisted of 64 pregnant and received only drug Potassium iodide-200".

The control correction was carried out by determination of the activity of iodine in whole blood by direct potentiometry using ion-selective electrodes firm "Crytur" (Czech Republic). the norm these figures are 20-50 µmol/L. A comprehensive clinical examination was carried out at registration at antenatal clinic and in the dynamics in terms 16-24, 28-32, 34-38 weeks.

Each group was divided into subgroups: control, anemic state with iron deficiency (J) and without iron deficiency (sidereactions anemic state - SA).

In the control subgroup upon receipt of Lamivudina notes approximation of the content of the iodides of blood to the lower limit of the norm. Women in this subgroup who did not receive the product, registered a sharp decline: 17,32±2,08 up for 9.47±2.58 mmol/L.

When anemic conditions involving iron deficiency, with the additional purpose of Lamivudina indicators of iodine blood conform to standards: 14.24 from±2.16 and 21,17±to 4.52 mmol/l In the absence of treatment-and-prophylactic product in the complex treatment of iodine deficiency in whole blood was offset slightly: of $ 11.97±1.96 and 13,23±4,72 µmol/L.

In the subgroup with anemic conditions sidereactions character at extra getting "Lamivudina" an increase of iodides blood of 16.84±3,44 µmol/L. When receiving only drug Potassium iodide-200" revealed reduced in 2 times: 12,32±2,23 and 6,15±1,79 µmol/L.

Based on studies done on purpose dieticheskogo the (therapeutic and prophylactic) of iodine-containing product Lamifiban" in addition to drugs, containing potassium iodide, we can say that the lack of iodine in the blood does not depend on the length of stay in iodine-deficient region. The purpose of the daily requirement of iodine in the form of the drug, "Potassium iodide-200" (pharmaceutical company "Berlin-Chemie") in terms of these provinces are not completely solves the issue of sufficient replenishment of iodine deficiency among the population, particularly in pregnant women.

More effectively implement comprehensive treatment IDS iodine preparations and therapeutic iodine-containing product Lamifiban".

Example 1.

Pregnant B., age 29 (thematic map pregnant No. 115), was registered at the antenatal clinic during pregnancy 25-26 weeks. This pregnancy - second. The woman belongs to the third generation living in the Khabarovsk territory. From extragenital disorders dystonia by mixed type, chronic pyelonephritis, the period of remission. Initial clinical and laboratory examination was possible to detect iron deficiency anemia (IDA) mild. Indicators of iodine in the blood were normal - 22,4 µmol/l Pregnant received basic therapy for the treatment of IDA and the daily requirement of iodine in the form of the drug, "Potassium iodide-200" in a dose of 200 mcg once a day, respectively, the generally accepted recommendations. Treatment-and-prophylactic PR is the product of a "Limitare" not received. During pregnancy, a survey of blood on the activity of iodine in 31-32, 36-37 weeks.

Despite the absence of iodine deficiency at the time of initial inspection and preventive intake of Potassium iodide in 200" marked decline in this indicator in the dynamics: the 14.8 µmol/l and 10.5 µmol/L.

Example 2.

Pregnant K., 26 (thematic map pregnant No. 151), was registered in female consultation with gestational age 10-11 weeks. This pregnancy - second. The woman arrived in Khabarovsk one year ago and belongs to the first generation living in the Khabarovsk territory. From extragenital diseases is chronic pyelonephritis, the period of remission. When the registration identified anemic condition with normal terradynamic, mild. Indicators of iodine in the blood were reduced to 7.08 mmol/l Pregnant received a vitamin energy complex and the drug Potassium iodide-200" in a dose of 200 mcg once a day. "Limitare" the woman did not accept. At follow-up examination was performed 3 times: 17-18, 30-31 and 34-35 weeks.

Despite treatment the drug of iodine Potassium iodide-200" remained low iodine blood: 5.5 µmol/l, 4,27 µmol/L.

Example 3.

Pregnant'clock, 20 years (thematic map pregnant No. 43), was registered in women's consultez the Yu of the pregnancy 15-16 weeks. This pregnancy - first. The woman belongs to the third generation living in the Khabarovsk territory. From extragenital disorders dystonia on hypotonic type, chronic gastritis, the period of remission. At the primary treatment the woman was conducted clinical and laboratory examination. Hematological and blood biochemical parameters were consistent with latent iron deficiency (LG). The determination of the activity of iodine in whole blood by the above method showed a lack of iodine - of 5.89 mmol/l (at a rate of 20-50 µmol/l). In addition to the basic therapy for the treatment LJ woman received the drug Potassium iodide-200" (pharmaceutical company Berlin-Chemie) at a dose of 200 µg, corresponding to daily needs, throughout pregnancy.

Additionally, he was appointed medical-prophylactic iodine-containing product "Limitare" in a dose of 50 g daily in the morning for 30-40 minutes before meals. Medicinal product was prescribed 2 courses in terms 15-16 and 31-32 weeks to 2 months. The study was conducted whole blood at 22-23, 28-29 and at 35-36 weeks of gestation.

Showed normalization of indicators of iodine blood towards the end of pregnancy: 6,46 µmol/l, 17.8 µmol/l, 21,38 µmol/l, respectively.

Example 4.

Pregnant So, 31 (thematic map pregnant No. 165), was registered in female consultation with cf is ke pregnancy 12-13 weeks. This pregnancy - second. The woman lives in Khabarovsk Krai 3 years and belongs to the first generation living in the region. From extragenital disorders common low back pain. At the primary treatment the woman was conducted clinical and laboratory examination. Abnormalities in hematological and biochemical blood parameters were not. Deficiency of iodine in the blood was reached 7,24 µmol/l (at a rate of 20-50 µmol/l). The woman received a multivitamin for pregnant women (without elements), the drug Potassium iodide-200" ("Berlin-Chemie").

Additionally, pregnant took therapeutic product "Limitare" in the proposed scheme. The study of whole blood at 17-18, 30-31 and 35-36 weeks of gestation showed positive results of the treatment: to 18.6 µmol/l, was 9.33 mmol/l, 33,1 µmol/L. Indicators of iodine blood before the birth corresponded to the norm.

Thus, treatment-and-prophylactic iodine-containing product "Lamifiban" should be recommended for the prevention and treatment IDS in pregnant women as independent disease, and syndrome in various pathologies.

Table
Received "Limitare" n=84Not received "Limitare n=64
The control group
Before taking17,21±of 2.5117,32±2,08
After takingof 19.03±4,99for 9.47±2,58
Anemic state with iron deficiency (J)
Before taking14.24 from±2,16of $ 11.97±1,96
After taking21,17±+to 4.5213,23±4,72
Anemic state without iron deficiency (sidereactions - SA)
Before taking12,71±2,3612,32±2,23
After takingof 16.84±3,446,15±1,79

A method of treating deficiency conditions in pregnant women, consisting in the use of iodine-containing preparations, characterized in that it further designate "Lamifiban" 50 g 1 in the morning for 30-40 minutes before eating natural fruit juices or milk products daily for 2 months after the initial survey.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves administering means produced as water containing 99.76-99.99 molecular percents of light 1H216O isotopolog and other isotopologs completing to 100%. Treatment method involves administering effective quantity of the above means in oral or parenteral way. The method additionally involves giving succinic acid or its pharmaceutical salt at a dose of 0.1-50 mg/kg.

EFFECT: enhanced effectiveness in selectively evoking apoptosis in transformed cells.

5 cl, 2 dwg, 7 tbl

FIELD: medicine, food processing industry.

SUBSTANCE: claimed enterosorbent contains 45-80 mass % of polysaccharide and balance: boehmite. As polysaccharide enterosorbent contains chitosan or lignin, or microcrystalline cellulose. Enterosorbent of present invention is useful in excretion of toxic substances from organism, prophylaxis of heavy metal intoxication, etc.

EFFECT: enterosorbent with high adsorption ability in relation to heavy metal ions; application only one kind of polysaccharide.

2 cl, 1 ex, 3 tbl, 2 dwg

FIELD: medicine, endocrinology, in particular treatment of diabetus mellitus type 2 in patient didn't use anti-diabetic drugs.

SUBSTANCE: claimed method includes simultaneous administration of metformine in daily dose of 160-750 mg and gliburide in daily dose of 0.5-15 mg. Gliburide has grain-size classification wherein min.10 % particles have size less than 2 mum and max.10 % particles have size more than 60 mum.

EFFECT: treatment of improved effectiveness with decreased drug doses and reduced side effects.

24 cl, 10 dwg, 4 ex, 4 tbl

FIELD: medicine, oncology, pharmacy.

SUBSTANCE: invention relates to pharmaceutical compositions used for inhibition of metastasis or prophylaxis of malignant tumor relapse after the topical therapy. As an active component, compositions contain derivative of polysaccharide comprising polysaccharide with carboxyl group bound with an active substance possessing anti-tumor activity through amino acid or peptide consisting of from 2 to 8 amino acids that are similar or different, or its salt wherein this active anti-tumor substance is represented by derivative of camptothecin of the formula (I) by claim 1 or compound of the formula (II) by claim 1 given in the invention description. The topical therapy involves surgery, radiation therapy, thermotherapy, cryotherapy or laser-burning therapy. Proposed compositions allow providing the high concentration of active substance in tumor metastasis region and prophylaxis of relapses of malignant tumor after carrying out the topical therapy.

EFFECT: valuable medicinal properties of pharmaceutical compositions, improved method of treatment.

9 cl, 1 dwg, 4 tbl, 6 ex

FIELD: medicine, pediatric gastroenterology.

SUBSTANCE: the present innovation deals with selecting children with functional dyspepsia at helicobacteriosis for the purpose to carry out anti-helicobacter therapy. So, one should detect the following signs in a child: hypertrophic gastropathy in gastric antral department, relapses of dyspepsia symptoms during 1 yr and more, despite treatment by applying antacids and anti-secretory preparations, inheritance on ulcerous disease, previously observed erosions in gastroduodenal area; and in case of any of the above-mentioned signs in a child it is necessary to fulfill anti-helicobacter therapy, and in case of the absence of the above-mentioned signs this therapy should not be carried out. This innovation provides differentiated approach to therapy, it, also, enables to avoid groundless medicinal loading upon a child and decrease financial expenses for the treatment.

EFFECT: higher efficiency of individualization.

4 ex

FIELD: medicine.

SUBSTANCE: claimed method includes blending of active base and auxiliary ingredients to form tablet corn, representing composition of sugar powder, monocrystalline cellulose, vinylpyrrolidone and calcium stearate; humidifying of obtained mixture; drying of obtained granules; dry granulation through granulator with standardized holes; pelletization of standardized granules to produce tablet corn; and coating. Mixture is humidified with 5-7 % starch mucilage in starch mucilage/humidifying mixture mass ratio of 1:25-30, wherein mixture is blending with starch mucilage for homogeneous distribution wet in whole mass.

EFFECT: tablets with increased hardness and enhanced pharmacological activity.

2 cl, 2 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new N-acylated pseudodipeptides comprising acidic group in neutral or charged form by one end of pseudodipeptide and accessory functionalized branching by the opposite end and corresponding to the general formula (I): wherein each R1 and R2 means acyl group of saturated or unsaturated, linear or branched carboxylic acid comprising from 2 to 24 carbon atoms, unsubstituted or comprising a substitute or substitutes chosen from hydroxyl, alkoxy- and acyloxy-groups; coefficient n has values from 0 to 3; coefficients p and q have values from 1 to 3; coefficient m has values from 1 to 3 except for a case when X means carboxyl or one of its derivative, and in this case it means values form 0 to 3; Y means oxygen atom (O) or -NH; X and Z mean accessory functionalized branching or acidic group in neutral or charged form chosen from the following groups: carboxyl, carboxy-(C1-C5)-alkoxy-, carboxy-(C1-C5)-alkylthio-, phosphono-(C1-C5)-alkoxy-, dihydroxyphosphoryloxy-, hydroxysulfonyloxy-, (carboxy-(C1-C5)-alkyl)aminocarbonyl, (dicarboxy-(C1-C5)-alkyl)aminocarbonyl, (ammonio-(C1-C5)-aminocarbonyl, carboxy-(amino-(C1-C5)-alkyl)aminocarbonyl under condition that at least one substitute among X and Z means an accessory functionalized branching, and their enantiomers and diastereoisomers. Proposed compounds show immunomolulating properties as adjuvants and these compounds can be grafted to antigen to modulate the immune response or can be grafted to pharmacophore to improve the therapeutic effect or its directed delivery.

EFFECT: improved preparing methods, improved and valuable medicinal properties of substances and compositions.

48 cl, 3 tbl, 112 dwg, 5 ex

FIELD: organic chemistry, medicine, oncology, pharmacy.

SUBSTANCE: invention relates to new sulfonamide derivatives possessing anti-tumor activity, namely to compounds of the formula (I): wherein R6 means hydroxyl; R7 means methyl, isopropyl, isobutyl, benzyl or indole-3-ylmethyl; R8 means hydrogen atom; R9 means phenylene; R10 means thienyl, furyl or pyridyl optionally substituted with lower alkyl or halogen atom. Also, invention relates to their derivatives or pharmaceutically acceptable salts or solvates. Invention describes medicinal agents used in treatment or prophylaxis of cancer and for prophylaxis of metastasis. Also, invention describes a case for treatment of cancer in mammal.

EFFECT: improved treatment method, valuable medicinal properties of agent.

5 cl, 17 tbl, 112 ex

FIELD: organic chemistry, medicine, oncology, pharmacy.

SUBSTANCE: invention relates to new sulfonamide derivatives possessing anti-tumor activity, namely to compounds of the formula (I): wherein R6 means hydroxyl; R7 means methyl, isopropyl, isobutyl, benzyl or indole-3-ylmethyl; R8 means hydrogen atom; R9 means phenylene; R10 means thienyl, furyl or pyridyl optionally substituted with lower alkyl or halogen atom. Also, invention relates to their derivatives or pharmaceutically acceptable salts or solvates. Invention describes medicinal agents used in treatment or prophylaxis of cancer and for prophylaxis of metastasis. Also, invention describes a case for treatment of cancer in mammal.

EFFECT: improved treatment method, valuable medicinal properties of agent.

5 cl, 17 tbl, 112 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of diphenylazathedinone of the general formula (I): wherein R1, R2, R3 and R4 mean independently of one another (0-C30)-alkylene-L wherein one or some C-atoms of alkylene residue can be substituted with -O-, -(C=O)- or -NH- and, except for, R1-R6 can represent hydrogen atom (H), fluorine atom (F), and L represents compound of the formula: , and their pharmaceutically tolerated salts also. Compounds of the formula (I) elicit hypolipidemic effect and can be used in therapeutic aims. Also, invention describes a medicinal agent and its using.

EFFECT: valuable medicinal properties of compounds.

7 cl, 31 ex

FIELD: medicine.

SUBSTANCE: method involves introducing Mirtilene forte at a dose of 1 pill twice a day and 1% Emoxipini solution at a parabulbar dose of daily as drug therapy component in combined treatment course comprising also magnetic therapy, laser stimulation of macular retina zone and pattern-stimulation. The total treatment course is 10 days long.

EFFECT: enhanced effectiveness of treatment.

2 cl

FIELD: cosmetology, esthetic surgery, applied biopharmacology.

SUBSTANCE: invention relates to medicative and cosmetic agents, and uses of biologically active substances based on natural biological complexes. Claimed method includes application of Mirralgin balm having analgesic, anti-inflammation and resolving action, Reventon balm, having vessel restorative action, for edema reducing and microcirculation improving. In process of blepharoplastic eye boundary bandage microemulsion having recovery and animative action on eaves skin is applied, and in process of facelifting cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied. Mirralgin balm and Reventon balm treatment is carried out sequentially or alternatively. In another embodiment after skin cleaning and treatment of damaged zone with anti-septic agent Bacteriophage gel, which disinfects skin surface, prevents biofilm forming, accelerates cicatrizing process is applied, then posttraumatic zone is treated with cleaning milk, toned up with tonic lotion and cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied.

EFFECT: method for skin structure recovering without skin trauma.

4 cl, 7 ex, 1 tbl

FIELD: cosmetology, esthetic surgery, applied biopharmacology.

SUBSTANCE: invention relates to medicative and cosmetic agents, and uses of biologically active substances based on natural biological complexes. Claimed method includes application of Mirralgin balm having analgesic, anti-inflammation and resolving action, Reventon balm, having vessel restorative action, for edema reducing and microcirculation improving. In process of blepharoplastic eye boundary bandage microemulsion having recovery and animative action on eaves skin is applied, and in process of facelifting cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied. Mirralgin balm and Reventon balm treatment is carried out sequentially or alternatively. In another embodiment after skin cleaning and treatment of damaged zone with anti-septic agent Bacteriophage gel, which disinfects skin surface, prevents biofilm forming, accelerates cicatrizing process is applied, then posttraumatic zone is treated with cleaning milk, toned up with tonic lotion and cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied.

EFFECT: method for skin structure recovering without skin trauma.

4 cl, 7 ex, 1 tbl

FIELD: cosmetology, in particular cosmetic and/or dermatological agents.

SUBSTANCE: claimed emulsion contains perfluorocarbons, water, oil phase and emulsifier. Additionally oil phase contains essential oil as agent for increased oxygen utilization by skin. Emulsion of present invention allows skin saturation with oxygen and expedites oxygen utilization interruption by skin.

EFFECT: emulsion increasing oxygen utilization rate in all epidermis layers.

4 cl, 1 ex, 1 tbl, 3 dwg

FIELD: cosmetology, in particular cosmetic and/or dermatological agents.

SUBSTANCE: claimed emulsion contains perfluorocarbons, water, oil phase and emulsifier. Additionally oil phase contains essential oil as agent for increased oxygen utilization by skin. Emulsion of present invention allows skin saturation with oxygen and expedites oxygen utilization interruption by skin.

EFFECT: emulsion increasing oxygen utilization rate in all epidermis layers.

4 cl, 1 ex, 1 tbl, 3 dwg

FIELD: spatial engineering.

SUBSTANCE: method of preparing freely standing spatial formulation containing liquid carrier, wherein solidification agent is dispersed, involves pumping formulation at temperature allowing introduction of formulation into inlet of tube, which also has outlet and is provided with cooling device so that formulation is discharged through tube outlet in freely standing state.

EFFECT: simplified procedure allowing utilization thereof for a variety of products.

27 cl, 3 dwg, 3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to brown algae-based medicative and prophylaxis preparation for treatment of periodontum inflammations. Claimed composition contains extract obtained from Ascophylum nodosum and Fucus vesiculous algae and water in the next mass ratio (gram): extract 1: water 100.

EFFECT: preparation stimulating lactobacterium production and not causing mouth cavity dysbacteriosis.

23 tbl

FIELD: veterinary.

SUBSTANCE: one should preliminarily dissolve 0.1 g sodium selenite dried up to constant weight in glycerol at phase ratio being 1:10 at heating at water bath at 60° C, or at phase ratio being 1:20 at 20° C at mixing, then the obtained solution should be supplemented with 100 g corn germs oil at constant mixing to obtain homogeneous solution. The innovation could be applied to obtain preparation for regulating metabolic processes in animal bodies. The method provides remedy containing natural biologically active complexes to enhance its antioxidant action.

EFFECT: higher efficiency.

FIELD: medicine, in particular agent for hand cleaning without water application.

SUBSTANCE: claimed agent contains polyvinyl alcohol bearing 8-13 of acetate groups and having dynamic viscosity from 23 to 47 Pa.c.103, or mixture of polyvinyl alcohol bearing 0.8-2.0 of acetate groups and having dynamic viscosity from 17 to 25 Pa.c.103 with polyvinyl alcohol bearing 8-13 of acetate groups and having dynamic viscosity from 16 to 19 Pa.c.103 in ratio of 1:(0.4-1.5), ethanol and water. Additionally agent contains PEG-40 and hydrogenised castor oil in specific ratio (mass %).

EFFECT: agent for hand cleaning applicable at minus temperatures without losses of consumption properties.

8 cl, 2 ex

FIELD: antiperspirant deodorant products.

SUBSTANCE: claimed product contains salt with antiperspirant activity and water soluble polymer, containing Bronsted acids, which acts as co-thickener when blending with antiperspirant salt in presence of water. Before application polymer is physically divided from antiperspirant salt.

EFFECT: antiperspirant product of improved effectiveness.

21 cl, 7 ex, 7 tbl

FIELD: medicine.

SUBSTANCE: method involves introducing Mirtilene forte at a dose of 1 pill twice a day and 1% Emoxipini solution at a parabulbar dose of daily as drug therapy component in combined treatment course comprising also magnetic therapy, laser stimulation of macular retina zone and pattern-stimulation. The total treatment course is 10 days long.

EFFECT: enhanced effectiveness of treatment.

2 cl

Up!